close

Agreements

1 210 211 212
Number of results: 4239

Excel print is not allowed for data more than 3000.Please search above for fewer data.

Date Company Compound Disease Type of agreement Therapeutic area Type of Information
2011-01-05 Selexis (Switzerland) Neogenix Oncology (USA) production cell line expressing Neogenix NPC-1C

licensing
commercialisation

Licensing agreement
2011-01-04 Santaris Pharma (Denmark) Pfizer (USA - NY) RNA-targeted medicines using Santaris Pharma A/S Locked Nucleic Acid (LNA) Drug Platform.

R&D
Commercialisation

R&D agreement
2011-01-04 Argenta (Galapagos subsidiary – UK Belgium) Dr. Reddy's Laboratories (India) pain-inflammation

development
commercialisation

CNS diseases - Inflammatory diseases Development agreement
2011-01-04 Kinaxo Biotechnology (Germany) AstraZeneca (UK) drug targets

R&D

Cancer Oncology R&D agreement
2011-01-04 Servier (France) Xoma (USA - CA) gevokizumab (Xoma 052) Behcet\'s uveitis, inflammatory diseases, cancer Cancer - Oncology - Inflammatory diseases - Rare diseases Development agreement
2011-01-03 Mercator Therapeutics (USA) Pepscan Therapeutics (The Netherlands) optimization of homing peptides tumors

R&D

Cancer - Oncology R&D agreement
2010-01-10 Bind Biosciences (USA - MA)

nomination

Nomination
2010-01-06 Amsterdam Molecular Therapeutics (The Netherlands) - consortium led by Institut Pasteur (France) adeno-associated viral 5 (AAV5) gene therapy Sanfilippo B (rare autosomal recessive lysosomal storage disease, which manifests in young children)

Development
Manufacturing
Production

Rare diseases Development agreement
0201-10-06 Horizon Discovery (UK) Haplogen Genomics (Austria) CRISPR/Cas9 human haploid cell line generation service and human haploid knock-out cell lines catalog

distribution

Technology - Services Distribution agreement
0000-00-00 ViiV Healthcare (UK - USA) the Medicines Patent Pool Tivicay® (dolutegravir) HIV1-infection

collaboration

Infectious diseases Collaboration agreement
0000-00-00 Ipsen (France)

nomination

Nomination
0000-00-00 Santen Pharmaceutical (Japan) new European Head Quarters in Geneva

opening of new premises

Ophtalmological diseases Opening of new premises
0000-00-00 Bluebird bio (USA - MA)

resignation

Resignation
0000-00-00 Ascendis Pharma (Denmark)

nomination

Nomination
0000-00-00 Macrogenics (USA - MD) Synthon (The Netherlands) MGC018,

licensing

development

Cancer - Oncology - Technology - Services Licensing agreement
0000-00-00 Macrogenics (USA - MD) Synthon (The Netherlands) MGC018,

licensing

development

Cancer - Oncology - Technology - Services Licensing agreement
0000-00-00 Loxo Oncology (USA - CT) Ventana Medical Systems,(USA), a member of the Roche Group (Switzerland) companion diagnostic to identify patients across tumor types suitable for treatment with larotrectinib Cancer - Oncology - Diagnostic Establishment of a new subsidiary in the EU
0000-00-00 OSE Immunotherapeutics (France) Memorial Sloan Kettering Cancer Center (USA - NY) OSE-703 (Effi-3) solid tumors, non-small cell lung cancer (NSCLC) research Cancer - Oncology Research agreement
0000-00-00 Race Oncology (Australia) TargImmune Therapeutics (Switzerland) Race Immunotherapeutics bisantrene combined with TargImmune's targeted cancer therapy technology joint-venture Cancer - Oncology Joint-venture agreement